The largest community of pharma leaders

John McCabe Joins Oncorus, Inc. as Chief Financial Officer

CAMBRIDGE, Mass.–()–Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of John McCabe as Chief Financial Officer (CFO). Prior to joining Oncorus, Mr. McCabe served as CFO of Flex Pharma, Inc., which is now known as Salarius Pharmaceuticals, Inc.

“We are thrilled to welcome John to the Oncorus team,” said Theodore (Ted) Ashburn, President and CEO of Oncorus. “We continue to grow and build out key functions as we advance our lead viral immunotherapy candidate, ONCR-177, toward the clinic, bolstered by the completion of our recent $79.5 million Series B financing. John’s comprehensive leadership expertise in corporate finance and accounting at both emerging and well-established biotechnology companies will be critical in helping us realize our vision to rapidly develop best-in-class intratumorally and intravenously administered viral immunotherapies to transform outcomes for cancer patients.”

Prior to joining Flex Pharma in 2014, Mr. McCabe served as Vice President and Chief Accounting Officer with ARIAD Pharmaceuticals, Inc. from 2013 to 2014, which was acquired by Takeda Pharmaceuticals, Ltd., and is now part of Takeda Oncology Company. Previously, Mr. McCabe served as Vice President and Corporate Controller at Charles River Associates from 2009 to 2013, where he was responsible for all aspects of global financial accounting, planning and reporting. Mr. McCabe also previously served as Director and Strategic Business Unit Controller at Biogen, managing all accounting and government pricing functions for the U.S. commercial business. Mr. McCabe began his career at Arthur Andersen & Co., and he later held financial positions at Performance Technologies, Inc. and

Mr. McCabe holds B.S. degrees in accounting and management information systems from Babson College, and an M.B.A from the University of Massachusetts at Amherst.

“It’s a privilege to join Ted and the Oncorus team at this exciting time for the company,” said Mr. McCabe. “The potential for viral immunotherapies to address the severe, unmet treatment needs that so many cancer patients unfortunately face is significant. With its novel innovations, proprietary intellectual property portfolio, top-notch talent and leadership, and mission-driven culture, Oncorus has the elements to deliver substantial impact for patients. I’m thrilled to have the opportunity to contribute to this company’s journey.”

About Oncorus

At Oncorus, we are driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. We are advancing a portfolio of intratumorally and intravenously administered viral immunotherapies for multiple indications with significant unmet needs based on our oncolytic herpes simplex virus-1 and synthetic virus platforms. Our team has engineered proprietary, multidimensional innovations into both platforms to enable us to deliver on the full potential of this therapeutic class to dramatically improve outcomes for cancer patients. Please visit to learn more.


Recent Articles